[PAR] [TLE] Alectinib [SEP] Alectinib (INN, marketed as Alecensa) is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC).  It was developed by Chugai Pharmaceutical Co. Japan, which is part of the Hoffmann-La Roche group. [PAR] [TLE] Hoffmann-La Roche [SEP] F. Hoffmann-La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics.  Its holding company, Roche Holding AG, has bearer shares listed on the SIX Swiss Exchange.  The company headquarters are located in Basel.
[PAR] [TLE] Alectinib [ SEP ] Alectinib ( INN , marketed as Alecensa ) is an oral drug that blocks the activity of anaplastic lymphoma kinase ( ALK ) and is used to treat non - small - cell lung cancer ( NSCLC ) . It was developed by Chugai Pharmaceutical Co. Japan , which is part of the Hoffmann - La Roche group . [PAR] [TLE] Hoffmann - La Roche [ SEP ] F. Hoffmann - La Roche AG is a Swiss multinational healthcare company that operates worldwide under two divisions : Pharmaceuticals and Diagnostics . Its holding company , Roche Holding AG , has bearer shares listed on the SIX Swiss Exchange . The company headquarters are located in Basel .
Alectinib developed by Hoffmann-La Roche is used to treat which type of cancer?
Alectinib developed by Hoffmann - La Roche is used to treat which type of cancer ?
non-small-cell lung cancer
non-small-cell lung cancer